沙库巴曲/缬沙坦与依那普利对心力衰竭合并糖尿病患者血糖控制的影响:PARADIGM-HF试验的事后分析
该研究为PARADIGM-HF试验的事后分析,纳入3778例已知糖尿病或筛查时HbA1c≥6.5%的射血分数降低的心力衰竭(HFrEF)患者,比较沙库巴曲/缬沙坦与依那普利对HbA1c及启动胰岛素或口服降糖药时间的影响。结果显示沙库巴曲/缬沙坦组HbA1c降幅更大,新启用胰岛素风险更低,提示沙库巴曲/缬沙坦可能改善此类患者的血糖控制。
要点
- 沙库巴曲/缬沙坦组随访第一年HbA1c降低0.26%,依那普利组降低0.16%,组间差值0.13%(95%CI 0.05-0.22,p=0.0023)。
- 3年随访期间沙库巴曲/缬沙坦组HbA1c持续低于依那普利组,组间差值0.14%(95%CI 0.06-0.23,p=0.0055)。
- 沙库巴曲/缬沙坦组新启用胰岛素风险较依那普利组低29%(HR 0.71,95%CI 0.56-0.90,p=0.0052)。
核心结论
- 在PARADIGM-HF试验纳入的糖尿病合并HFrEF患者中,接受沙库巴曲/缬沙坦者长期HbA1c降幅大于接受依那普利者。
- 这些数据提示沙库巴曲/缬沙坦可能改善糖尿病合并HFrEF患者的血糖控制。
研究设计与样本
- PARADIGM-HF试验的事后分析,从8399例HFrEF患者中纳入3778例已知糖尿病或筛查时HbA1c≥6.5%者,随机接受沙库巴曲/缬沙坦或依那普利治疗,其中大多数(98%)为2型糖尿病。
- 采用混合效应纵向分析模型评估HbA1c、甘油三酯、HDL胆固醇和BMI的变化,并比较两组既往未使用降糖药物者启动口服降糖药或胰岛素的时间。
主要发现
- 筛查时随机分组间HbA1c浓度无显著差异。
- 随访第一年,依那普利组HbA1c降低0.16%(SD 1.40),沙库巴曲/缬沙坦组降低0.26%(SD 1.25),组间降幅差0.13%(95%CI 0.05-0.22,p=0.0023)。
- 3年随访期间沙库巴曲/缬沙坦组HbA1c持续低于依那普利组,组间降幅差0.14%(95%CI 0.06-0.23,p=0.0055)。
- 沙库巴曲/缬沙坦组新启用胰岛素者114例(7%),依那普利组153例(10%),新启用胰岛素风险降低29%(HR 0.71,95%CI 0.56-0.90,p=0.0052)。
- 沙库巴曲/缬沙坦组启动口服降糖治疗者较少(HR 0.77,95%CI 0.58-1.02,p=0.073)。
关键数值与推荐
- 糖尿病定义为已知糖尿病或筛查时HbA1c≥6.5%。
- 主要比较指标为HbA1c变化及首次启动胰岛素或口服降糖药的时间。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diabetes is an independent risk factor for heart failure progression. Sacubitril/valsartan, a combination angiotensin receptor-neprilysin inhibitor, improves morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF), compared with the angiotensin-converting enzyme inhibitor enalapril, and improves peripheral insulin sensitivity in obese hypertensive patients. We aimed to investigate the effect of sacubitril/valsartan versus enalapril on HbA1c and time to first-time initiation of insulin or oral antihyperglycaemic drugs in patients with diabetes and HFrEF. METHODS: In a post-hoc analysis of the PARADIGM-HF trial, we included 3778 patients with known diabetes or an HbA1c ≥6·5% at screening out of 8399 patients with HFrEF who were randomly assigned to treatment with sacubitril/valsartan or enalapril. Of these patients, most (98%) had type 2 diabetes. We assessed changes in HbA1c, triglycerides, HDL cholesterol and BMI in a mixed effects longitudinal analysis model. Time to initiation of oral antihyperglycaemic drugs or insulin in subjects previously not treated with these agents were compared between treatment groups. FINDINGS: There were no significant differences in HbA1c concentrations between randomised groups at screening. During the first year of follow-up, HbA1c concentrations decreased by 0·16% (SD 1·40) in the enalapril group and 0·26% (SD 1·25) in the sacubitril/valsartan group (between-group reduction 0·13%, 95% CI 0·05-0·22, p=0·0023). HbA1c concentrations were persistently lower in the sacubitril/valsartan group than in the enalapril group over the 3-year follow-up (between-group reduction 0·14%, 95% CI 0·06-0·23, p=0·0055). New use of insulin was 29% lower in patients receiving sacubitril/valsartan (114 [7%] patients) compared with patients receiving enalapril (153 [10%]; hazard ratio 0·71, 95% CI 0·56-0·90, p=0·0052). Similarly, fewer patients were started on oral antihyperglycaemic therapy (0·77, 0·58-1·02, p=0·073) in the sacubitril/valsartan group. INTERPRETATION: Patients with diabetes and HFrEF enrolled in PARADIGM-HF who received sacubitril/valsartan had a greater long-term reduction in HbA1c than those receiving enalapril. These data suggest that sacubitril/valsartan might enhance glycaemic control in patients with diabetes and HFrEF. FUNDING: Novartis.
引用
- Seferovic JP, Claggett B, Seidelmann SB, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017. PMID: 28330649. doi:10.1016/S2213-8587(17)30087-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。